More than half of patients with microsatellite-stable metastatic colorectal cancer without active liver metastases survived at least 18 months with botensilimab plus balstilimab.
|Articles|July 1, 2000
Oncology NEWS International
- Oncology NEWS International Vol 9 No 7
- Volume 9
- Issue 7
New Drug Information Website
BETHESDA, Md-Patients have a new, reliable source for information about drugs. The National Library of Medicine has added the US Pharmacopeia’s Drug Information, Vol. II, “Advice for the Patient,” to its MEDLINEplus website. The publication provides extensive information about more than 9,000 brand name, generic prescription, and over-the-counter medications, written in nontechnical language. The information is available at http://medlineplus.gov.
Advertisement
BETHESDA, MdPatients have a new, reliable source for information about drugs. The National Library of Medicine has added the US Pharmacopeias Drug Information, Vol. II, Advice for the Patient, to its MEDLINEplus website. The publication provides extensive information about more than 9,000 brand name, generic prescription, and over-the-counter medications, written in nontechnical language. The information is available at
Articles in this issue
over 26 years ago
Couric Urges Doctors to Talk to Patients About Colon Cancerover 26 years ago
Automated Imaging Notification System Close to Fail-Safeover 26 years ago
Higher Dairy Consumption Linked to Prostate Cancer Riskover 26 years ago
First-Year Funding of Early Detection Research Network Completeover 26 years ago
Gritty Antitobacco Ads and More From Legacy Foundationover 26 years ago
Tositumomab Effective for Low-Grade Follicular Lymphomaover 26 years ago
New Awards Spotlight Courage of Cancer Survivorsover 26 years ago
Hospital Volume Shown to Predict Breast Cancer Outcomeover 26 years ago
NCCN Presents Updated Colorectal Cancer Guidelinesover 26 years ago
Taxol Teamed With Herceptin Tested Against Prostate CancerAdvertisement
Related to this article
Investigators will present detailed findings from a phase 2 study assessing a tambiciclib-based regimen in patients with relapsed/refractory AML at ASH 2026.
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists perform brachytherapy, and one setting where he considers it the better option.
Chinmay Jani, MD, discusses ASCO 2026 data on lung cancer trends in younger adults and why this group has been overlooked.
Data from the OrigAMI-4 trial support the accelerated approval of amivantamab and hyaluronidase-lpuj for this HNSCC population.
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.
Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.
Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
FDA Sets PDUFA Date for Rivoceranib/Camrelizumab Resubmission After Third CRL in Unresectable HCC
3
Sacituzumab Govitecan Efficacy, Safety Debated in First-Line Metastatic TNBC
4
Air Pollution Emerges as Second Leading Risk Factor for Lung Cancer Deaths
5